以毛细血管再充盈时间为目标的个体化血流动力学复苏治疗早期脓毒性休克:ANDROMEDA-SHOCK-2随机临床试验
该随机临床试验在19个国家86个中心纳入脓毒性休克4小时内患者,比较以毛细血管再充盈时间为目标的个体化血流动力学复苏方案(720例)与常规治疗(747例)对28天死亡、生命支持持续时间及住院时间的分层复合结局的影响,主要分析纳入1467例。结果显示干预组胜算比为1.16(95%CI 1.02-1.33;P=0.04),优于常规治疗,主要归因于生命支持持续时间缩短。
要点
- 以毛细血管再充盈时间为目标的个体化复苏方案在分层复合结局上优于常规治疗,胜算比1.16(95%CI 1.02-1.33;P=0.04)。
- 干预组与常规组在生命支持持续时间上的胜算分别为26.4%与21.1%,是复合结局优势的主要来源。
- 死亡单项胜算干预组19.1% vs 常规组17.8%,住院时间单项胜算3.4% vs 3.2%。
核心结论
- 在早期脓毒性休克患者中,以毛细血管再充盈时间为目标的个体化血流动力学复苏方案在主要复合结局上优于常规治疗,主要归因于生命支持持续时间缩短。
研究设计与样本
- 本研究为随机临床试验,在19个国家86个中心开展,纳入脓毒性休克4小时内患者,干预组720例、常规治疗组747例,主要分析纳入1467例(平均年龄66岁[标准差17],女性43.3%)。
主要发现
- 主要分层复合结局胜算:干预组131131次胜算(48.9%)vs 常规组112787次(42.1%),胜算比1.16(95%CI 1.02-1.33;P=0.04)。
- 死亡单项胜算干预组19.1% vs 常规组17.8%。
- 生命支持持续时间单项胜算干预组26.4% vs 常规组21.1%。
- 住院时间单项胜算干预组3.4% vs 常规组3.2%。
关键数值与推荐
- 干预方案包括评估脉压、舒张压、容量反应性及床旁超声心动图,以调整液体、血管升压药和正性肌力药。
- 主要结局为28天死亡、生命支持持续时间(血管活性药、机械通气及肾脏替代治疗)与住院时间构成的分层复合结局,按入院时APACHE II评分中位数分层计算胜算比。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The optimal strategy for hemodynamic resuscitation in early septic shock remains uncertain. OBJECTIVE: To determine the effect of a personalized hemodynamic resuscitation protocol targeting capillary refill time (CRT-PHR) on a hierarchical composite outcome of mortality, duration of vital support, and length of hospital stay. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial was conducted in 86 centers in 19 countries. Patients within the first 4 hours of septic shock were included between March 2022 and April 2025, with last follow-up in July 2025. INTERVENTIONS: Patients were randomized to undergo CRT-PHR (n = 720), including assessment of pulse pressure, diastolic arterial pressure, fluid responsiveness, and bedside echocardiography, to tailor fluids, vasopressors, and inotropes, vs usual care (n = 747). MAIN OUTCOMES AND MEASURES: The primary outcome was a hierarchical composite of mortality, duration of vital support (vasoactives, mechanical ventilation, and kidney replacement therapy), and length of hospital stay assessed at 28 days. A win ratio was calculated for the primary outcome by comparing all possible patient pairs, starting with the first event in the hierarchy and stratified by median APACHE (Acute Physiology and Chronic Health Evaluation) II score at admission. Secondary outcomes were mortality, vital support-free days, and length of hospital stay at 28 days. RESULTS: From 1501 randomized patients, 1467 were included in the primary analysis (mean age, 66 [17] years; 43.3% female). There were 131 131 wins (48.9%) in the CRT-PHR group vs 112 787 (42.1%) in the usual care group for the hierarchical composite primary outcome, with a win ratio of 1.16 (95% CI, 1.02-1.33; P = .04). Individual wins for death were 19.1% vs 17.8%; duration of vital support, 26.4% vs 21.1%; and length of hospital stay, 3.4% vs 3.2% in the intervention vs usual care groups, respectively. CONCLUSIONS AND RELEVANCE: Among patients with early septic shock, a personalized hemodynamic resuscitation protocol targeting capillary refill time was superior to usual care for the primary composite outcome, primarily due to a lower duration of vital support. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05057611.
引用
- Hernandez G, Ospina-Tascón GA, Kattan E, et al. Personalized Hemodynamic Resuscitation Targeting Capillary Refill Time in Early Septic Shock: The ANDROMEDA-SHOCK-2 Randomized Clinical Trial. JAMA. 2025. PMID: 41159835. doi:10.1001/jama.2025.20402
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。